An epitope-specific chemically defined nanoparticle vaccine for respiratory syncytial virus

Abstract Respiratory syncytial virus (RSV) can cause severe respiratory disease in humans, particularly in infants and the elderly. However, attempts to develop a safe and effective vaccine have so far been unsuccessful. Atomic-level structures of epitopes targeted by RSV-neutralizing antibodies are...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Armando Zuniga, Oliver Rassek, Melissa Vrohlings, Aniebrys Marrero-Nodarse, Kerstin Moehle, John A. Robinson, Arin Ghasparian
Formato:	article
Lenguaje:	EN
Publicado:	Nature Portfolio 2021
Materias:	Immunologic diseases. Allergy RC581-607 Neoplasms. Tumors. Oncology. Including cancer and carcinogens RC254-282
Acceso en línea:	https://doaj.org/article/adb559966dc64ff4b26148413e229c01
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:adb559966dc64ff4b26148413e229c01
record_format	dspace
spelling	oai:doaj.org-article:adb559966dc64ff4b26148413e229c012021-12-02T17:39:45ZAn epitope-specific chemically defined nanoparticle vaccine for respiratory syncytial virus10.1038/s41541-021-00347-y2059-0105https://doaj.org/article/adb559966dc64ff4b26148413e229c012021-06-01T00:00:00Zhttps://doi.org/10.1038/s41541-021-00347-yhttps://doaj.org/toc/2059-0105Abstract Respiratory syncytial virus (RSV) can cause severe respiratory disease in humans, particularly in infants and the elderly. However, attempts to develop a safe and effective vaccine have so far been unsuccessful. Atomic-level structures of epitopes targeted by RSV-neutralizing antibodies are now known, including that bound by Motavizumab and its clinically used progenitor Palivizumab. We developed a chemically defined approach to RSV vaccine design, that allows control of both immunogenicity and safety features of the vaccine. Structure-guided antigen design and a synthetic nanoparticle delivery platform led to a vaccine candidate that elicits high titers of palivizumab-like, epitope-specific neutralizing antibodies. The vaccine protects preclinical animal models from RSV infection and lung pathology typical of vaccine-derived disease enhancement. The results suggest that the development of a safe and effective synthetic epitope-specific RSV vaccine may be feasible by combining this conformationally stabilized peptide and synthetic nanoparticle delivery system.Armando ZunigaOliver RassekMelissa VrohlingsAniebrys Marrero-NodarseKerstin MoehleJohn A. RobinsonArin GhasparianNature PortfolioarticleImmunologic diseases. AllergyRC581-607Neoplasms. Tumors. Oncology. Including cancer and carcinogensRC254-282ENnpj Vaccines, Vol 6, Iss 1, Pp 1-9 (2021)
institution	DOAJ
collection	DOAJ
language	EN
topic	Immunologic diseases. Allergy RC581-607 Neoplasms. Tumors. Oncology. Including cancer and carcinogens RC254-282
spellingShingle	Immunologic diseases. Allergy RC581-607 Neoplasms. Tumors. Oncology. Including cancer and carcinogens RC254-282 Armando Zuniga Oliver Rassek Melissa Vrohlings Aniebrys Marrero-Nodarse Kerstin Moehle John A. Robinson Arin Ghasparian An epitope-specific chemically defined nanoparticle vaccine for respiratory syncytial virus
description	Abstract Respiratory syncytial virus (RSV) can cause severe respiratory disease in humans, particularly in infants and the elderly. However, attempts to develop a safe and effective vaccine have so far been unsuccessful. Atomic-level structures of epitopes targeted by RSV-neutralizing antibodies are now known, including that bound by Motavizumab and its clinically used progenitor Palivizumab. We developed a chemically defined approach to RSV vaccine design, that allows control of both immunogenicity and safety features of the vaccine. Structure-guided antigen design and a synthetic nanoparticle delivery platform led to a vaccine candidate that elicits high titers of palivizumab-like, epitope-specific neutralizing antibodies. The vaccine protects preclinical animal models from RSV infection and lung pathology typical of vaccine-derived disease enhancement. The results suggest that the development of a safe and effective synthetic epitope-specific RSV vaccine may be feasible by combining this conformationally stabilized peptide and synthetic nanoparticle delivery system.
format	article
author	Armando Zuniga Oliver Rassek Melissa Vrohlings Aniebrys Marrero-Nodarse Kerstin Moehle John A. Robinson Arin Ghasparian
author_facet	Armando Zuniga Oliver Rassek Melissa Vrohlings Aniebrys Marrero-Nodarse Kerstin Moehle John A. Robinson Arin Ghasparian
author_sort	Armando Zuniga
title	An epitope-specific chemically defined nanoparticle vaccine for respiratory syncytial virus
title_short	An epitope-specific chemically defined nanoparticle vaccine for respiratory syncytial virus
title_full	An epitope-specific chemically defined nanoparticle vaccine for respiratory syncytial virus
title_fullStr	An epitope-specific chemically defined nanoparticle vaccine for respiratory syncytial virus
title_full_unstemmed	An epitope-specific chemically defined nanoparticle vaccine for respiratory syncytial virus
title_sort	epitope-specific chemically defined nanoparticle vaccine for respiratory syncytial virus
publisher	Nature Portfolio
publishDate	2021
url	https://doaj.org/article/adb559966dc64ff4b26148413e229c01
work_keys_str_mv	AT armandozuniga anepitopespecificchemicallydefinednanoparticlevaccineforrespiratorysyncytialvirus AT oliverrassek anepitopespecificchemicallydefinednanoparticlevaccineforrespiratorysyncytialvirus AT melissavrohlings anepitopespecificchemicallydefinednanoparticlevaccineforrespiratorysyncytialvirus AT aniebrysmarreronodarse anepitopespecificchemicallydefinednanoparticlevaccineforrespiratorysyncytialvirus AT kerstinmoehle anepitopespecificchemicallydefinednanoparticlevaccineforrespiratorysyncytialvirus AT johnarobinson anepitopespecificchemicallydefinednanoparticlevaccineforrespiratorysyncytialvirus AT aringhasparian anepitopespecificchemicallydefinednanoparticlevaccineforrespiratorysyncytialvirus AT armandozuniga epitopespecificchemicallydefinednanoparticlevaccineforrespiratorysyncytialvirus AT oliverrassek epitopespecificchemicallydefinednanoparticlevaccineforrespiratorysyncytialvirus AT melissavrohlings epitopespecificchemicallydefinednanoparticlevaccineforrespiratorysyncytialvirus AT aniebrysmarreronodarse epitopespecificchemicallydefinednanoparticlevaccineforrespiratorysyncytialvirus AT kerstinmoehle epitopespecificchemicallydefinednanoparticlevaccineforrespiratorysyncytialvirus AT johnarobinson epitopespecificchemicallydefinednanoparticlevaccineforrespiratorysyncytialvirus AT aringhasparian epitopespecificchemicallydefinednanoparticlevaccineforrespiratorysyncytialvirus
_version_	1718379841352368128

An epitope-specific chemically defined nanoparticle vaccine for respiratory syncytial virus

Ejemplares similares